Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
The ZID regimen might offer deep remission and provide a time-limited Bruton's tyrosine kinase inhibitor therapy in patients with WM.
Authors
- Rui Lyu (ORCID: https://orcid.org/0000-0003-0302-7615)
- Wenjie Xiong (ORCID: https://orcid.org/0000-0002-0302-0408)
- Yi Wang (ORCID: https://orcid.org/0000-0002-0066-1234)
- Dehui Zou (ORCID: https://orcid.org/0000-0002-8135-4913)
- Lugui Qiu (ORCID: https://orcid.org/0000-0002-8752-0644)
- Gang An (ORCID: https://orcid.org/0000-0003-4922-4614)
- Shuhua Yi (ORCID: https://orcid.org/0000-0002-6291-812X)
- Tingyu Wang (ORCID: https://orcid.org/0000-0003-4542-3587)
- Yuting Yan (ORCID: https://orcid.org/0000-0002-9355-2984)
- Weiwei Sui (ORCID: https://orcid.org/0000-0002-6982-8258)
- Yan Xu (ORCID: https://orcid.org/0000-0002-6167-3319)
- Wei Liu (ORCID: https://orcid.org/0000-0002-0448-7210)
- Ying Yu (ORCID: https://orcid.org/0000-0001-7362-2925)
- Tengteng Yu (ORCID: https://orcid.org/0000-0003-4005-3003)
- Wenyang Huang
- Huimin Liu (ORCID: https://orcid.org/0009-0007-0175-3476)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3490
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25